Glycidol modulation of the immune responses in female B6C3F1 mice.
The immunotoxic potential of glycidol was evaluated in female B6C3F1 mice using a battery of functional assays and three host resistance models. Glycidol was administered to the animals by oral gavage as a solution in sterile distilled water daily for 14 days at doses of 25, 125 and 250 mg/kg. In tier I, we observed that glycidol exposure produced a dose-related decrease in splenocyte IgM antibody-forming cell response to sheep red blood cells (sRBC); the spleen natural killer (NK) cell activity was also decreased. A decrease in B cell proliferative responses to anti-IgM F(ab')2 and/or interleukin-4 (IL-4) was observed while the splenocyte proliferative responses to T cell mitogen ConA and B cell mitogen LPS were not affected. The splenocyte proliferative response to allogeneic cells as evaluated in the mixed leukocyte reaction (MLR) to DBA/2 spleen cells was not affected. In tier II, we found that exposure to glycidol decreased the number and percentage of B cells and the absolute number of CD4+ T cells in the spleen while the number of total T cells, CD8+ T cells and CD4+CD8+ T cells was not affected. The cytotoxic T lymphocyte (CTL) response to mitomycin C-treated P815 mastocytoma was not affected; the cytotoxic activity of peritoneal macrophages was not suppressed. Moreover, the host resistance to Listeria monocytogenes was not affected although a slight increase in host resistance to Streptococcus pneumoniae was observed. However, exposure to glycidol decreased host resistance to the B16F10 melanoma tumor model with the maximal tumor formation in lung observed in the high dose group. Overall, these dada support the finding that glycidol is an immunosuppressive agent in female B6C3F1 mice.
Guo
T L
TL
Department of Pharmacology and Toxicology, Virginia Commonwealth University, Richmond 23298-0613, USA.
McCay
J A
JA
Brown
R D
RD
Musgrove
D L
DL
Butterworth
L
L
Munson
A E
AE
Germolec
D R
DR
White
K L
KL
D000818:Animals; D000917:Antibody Formation / Q000187:drug effects; D000921:Antibody-Producing Cells / Q000187:drug effects*; D001402:B-Lymphocytes / Q000187:drug effects; D001835:Body Weight / Q000187:drug effects; D002273:Carcinogens / Q000008:administration & dosage / Q000633:toxicity*; D004305:Dose-Response Relationship, Drug; D004852:Epoxy Compounds / Q000008:administration & dosage / Q000633:toxicity*; D005260:Female; D007107:Immune System / Q000187:drug effects; D007109:Immunity / Q000187:drug effects; D007111:Immunity, Cellular; D007075:Immunoglobulin M / Q000276:immunology*; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000633:toxicity*; D007441:Intubation, Gastrointestinal; D007694:Killer Cells, Natural / Q000187:drug effects*; D008213:Lymphocyte Activation / Q000187:drug effects; D051379:Mice; D008815:Mice, Inbred Strains; D009929:Organ Size / Q000187:drug effects; D020005:Propanols / Q000008:administration & dosage / Q000633:toxicity*; D013154:Spleen / Q000187:drug effects* / Q000473:pathology; D018675:Toxicity Tests
D002273:Carcinogens; D004852:Epoxy Compounds; D007075:Immunoglobulin M; D007166:Immunosuppressive Agents; D020005:Propanols; C004312:glycidol